NASDAQ:TXMD

TherapeuticsMD Q2 2026 Earnings Results & Report

TherapeuticsMD logo
$1.71 -0.10 (-5.52%)
As of 04:00 PM Eastern

TherapeuticsMD beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released August 11, 2026. The company reported EPS of $0.01 versus the -$6.1250 consensus estimate, while revenue of $869 thousand fell short of the $19.77 million estimate by $18.90 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

TherapeuticsMD EPS Results

Actual EPS
$0.01
Consensus EPS
-$6.1250
Beat/Miss
Beat by +$6.1350
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

TherapeuticsMD Revenue Results

Actual Revenue
$869 thousand
Expected Revenue
$19.77 million
Beat/Miss
Missed by -$18.90 million
YoY Revenue Growth
N/A

TherapeuticsMD Q2 2026 Earnings FAQ

TherapeuticsMD (NASDAQ:TXMD) reported earnings of $0.01 per share for Q2 2026, beating the consensus estimate of -$6.1250. The report was announced on Tuesday, August 11, 2026.

TherapeuticsMD reported revenue of $869 thousand for Q2 2026, against a consensus estimate of $19.77 million.

TherapeuticsMD Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market.

The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women.

In 2023, TherapeuticsMD sold substantially all of its assets, including rights to these products, to Mayne Pharma. The products and commercial activities described here reflect TherapeuticsMD’s historical business.

View TherapeuticsMD Profile